DNA

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…

2 months ago

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading…

2 months ago

USDA Grants Amfora Exemption for Its Patented, Gene-Edited, Ultra-High Protein Soy, Accelerating Path to Market

SAN FRANCISCO, April 23, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS)…

2 months ago

Applied DNA Announces 1-For-20 Reverse Stock Split

STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company),…

2 months ago

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday,…

2 months ago

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ETCORAL GABLES, Fla.,…

2 months ago

OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th

BETHLEHEM, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call…

2 months ago

Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024

Treatment with EBT-104 resulted in over 90% reduction in viral shedding in HSV-1 Keratitis modelSAN FRANCISCO, April 22, 2024 (GLOBE…

2 months ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for…

2 months ago

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

2 months ago